Tag: delivery

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.

Anavar for Women is trending in 2025 as fitness-focused women seek safer, effective cutting support. Discover how Anvarol is emerging as a leading legal alternative tailored for lean muscle tone, stamina, and strength—without synthetic risk.

PhenQ 2025 OTC Fat Burner for Men: Medically accredited supplement gains national traction with expert-backed multi-action formula and user trust.

TALLINN, Estonia, July 12, 2025 (GLOBE NEWSWIRE) -- With interest in blockchain innovation surging, Bitcoin Solaris (BTC-S) is making headlines by rolling out a limited-time price rollback during its ongoing presale—now in Phase 11. Originally priced at $11, BTC-S tokens are now available for just $5, giving new buyers access to a lower entry point as the project approaches its official launch.

IOWA CITY, Iowa, July 11, 2025 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG) (“MidWestOne” or the “Company”), parent company of MidWestOne Bank, today announced that its second quarter 2025 financial results will be released after market closes on Thursday, July 24, 2025. The Company will host a conference call to discuss its financial results at 11:00 a.m. Central Time on Friday, July 25, 2025.

EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company’s board of directors granted one new non-executive employee 4,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) complied with federal securities laws. On July 8, 2025, RxSight announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance, revealing declines in revenue, Light Delivery Devices sales, and usage of Light Adjustable Lenses. Following this news, the price of the Company’s stock dropped. 

New York City, NY, July 11, 2025 (GLOBE NEWSWIRE) --

For decades, the use of muscle building steroids has been a driving force behind the pursuit of muscle growth and physical prowess among bodybuilders, athletes, and sports professionals.